PROVECTUS BIOPHARMS (PVCT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PVCT SEC filings page.
PROVECTUS BIOPHARMS (PVCT) reported $336K in revenue for fiscal year 2025, down 45.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported figures depict a development-stage company where research spending and financing support operations despite minimal revenue and shrinking assets.
Positive net income has not represented operating profitability: in FY2024, the company reported a net income of$4.8M alongside an operating loss of$4.5M and operating cash flow of-$3.3M . That combination indicates reported earnings were shaped by items outside ongoing operations, while the underlying business continued consuming cash.
Research spending exceeds revenue by a wide margin: FY2025 revenue was only
The balance sheet is heavily dependent on financing: FY2025 liabilities of
Financial Health Signals
PROVECTUS BIOPHARMS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
PROVECTUS BIOPHARMS's EBITDA was -$938K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 47.9% from the same quarter a year earlier. Against the prior quarter it is up 24.8%.
PROVECTUS BIOPHARMS reported -$983K in net income in Q2 2026. This represents an increase of 45.8% from the same quarter a year earlier. Against the prior quarter it is up 23.9%.
Not reported for Q2 2026.
Cash & Balance Sheet
PROVECTUS BIOPHARMS held $1.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
PROVECTUS BIOPHARMS invested $131K in research and development in Q2 2026. This represents a decrease of 85.1% from the same quarter a year earlier. Against the prior quarter it is down 60.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
PVCT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $57K-77.5% | $279K+17.0% | $14K-88.2% | $110K+57.4% |
| R&D Expenses | $131K-85.1% | $333K-17.2% | N/A | $346K-16.5% | $881K+86.3% | $403K-27.5% | $608K+46.3% | $414K+18.0% |
| SG&A Expenses | $808K-17.4% | $915K-6.1% | N/A | $930K+42.7% | $977K+69.4% | $974K+650.3% | $1.7M+461.6% | $651K+50.4% |
| Operating Income | -$939K+47.9% | -$1.2M-13.7% | N/A | -$1.3M-33.5% | -$1.8M-126.5% | -$1.1M-145.5% | -$2.3M-286.1% | -$956K-33.8% |
| EBITDA | -$938K+47.9% | -$1.2M-13.7% | N/A | -$1.3M-33.7% | -$1.8M-127.1% | -$1.1M-146.6% | -$2.3M-287.4% | -$953K-33.9% |
| Interest Expense | $50K+2416.0% | $53K-16.7% | N/A | -$48K+18.2% | $2K+103.3% | $64K+212.1% | $190K+16.6% | -$59K+4.6% |
| Net Income | -$983K+45.8% | -$1.3M-13.2% | N/A | -$1.3M-29.3% | -$1.8M-114.3% | -$1.1M-126.2% | N/A | -$1.0M-30.7% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Diluted Shares (Avg) | 420M0.0% | 420M0.0% | N/A | 420M+0.1% | 420M+0.2% | 420M+0.2% | N/A | 420M+0.1% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
PVCT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5M+104.0% | $578K-13.3% | $698K-30.7% | $420K-47.6% | $722K-15.7% | $666K-38.3% | $1.0M-30.5% | $802K-52.5% |
| Current Assets | $1.4M+140.9% | $460K-29.1% | $568K-41.9% | $278K-63.4% | $568K-29.0% | $649K-35.6% | $977K-28.4% | $760K-52.3% |
| Cash & Equivalents | $1.2M+199.8% | $224K-42.7% | $251K-18.3% | $72K-61.3% | $386K+1204.7% | $390K+2064.9% | $307K+301.5% | $187K-49.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.8M+17.6% | $7.3M+27.4% | $7.0M+0.4% | $6.6M+5.8% | $6.6M-21.2% | $5.7M-32.8% | $7.0M-22.9% | $6.2M-32.4% |
| Current Liabilities | $7.7M+18.7% | $7.2M+26.3% | $6.9M-1.1% | $6.5M+4.0% | $6.5M-22.4% | $5.7M-32.7% | $7.0M-22.6% | $6.2M-32.1% |
| Non-Current Liabilities | $54K-48.1% | $67K | $103K | $115K | $104K | $0-100.0% | $0-100.0% | $0-100.0% |
| Total Equity | -$6.3M-6.9% | -$6.7M-31.8% | -$6.3M-5.7% | -$6.2M-13.4% | -$5.9M+21.9% | -$5.1M+31.5% | -$6.0M+21.5% | -$5.4M+27.9% |
| Retained Earnings | -$265.1M-1.8% | -$264.1M-2.2% | -$262.9M-2.1% | -$261.7M-2.6% | -$260.4M-2.5% | -$258.6M-2.1% | -$257.4M-1.9% | -$255.1M-1.2% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PVCT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$358K+31.5% | -$358K+67.3% | -$870K+4.7% | -$840K-48.6% | -$523K+31.4% | -$1.1M-4.7% | -$912K-62.5% | -$565K+26.5% |
| Depreciation & Amortization | $466+0.2% | $466-0.2% | $465-0.2% | $466-79.1% | $465-79.1% | $467-79.1% | $466-79.1% | $2K0.0% |
| Stock-Based Compensation | $306K-5.0% | $306K-2.9% | N/A | $313K-67.1% | $322K | $315K | N/A | $949K |
| Financing Cash Flow | $1.3M+174.9% | $330K-69.3% | $1.0M+33.0% | $496K-15.9% | $470K-20.2% | $1.1M+37.4% | $788K+291.2% | $589K-27.9% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
PVCT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | -3132.8% | -394.1% | -16289.0% | -870.9% |
| Net Margin | N/A | N/A | N/A | N/A | -3156.6% | -409.2% | N/A | -924.3% |
| Return on Assets | -66.7%+184.5pp | -223.4%-52.3pp | N/A | -312.3%-185.8pp | -251.2%-152.3pp | -171.1%-124.4pp | N/A | -126.5%-80.6pp |
| Current Ratio | 0.18+0.1x | 0.060.0x | 0.08-0.1x | 0.04-0.1x | 0.090.0x | 0.110.0x | 0.140.0x | 0.12-0.1x |
| Asset Turnover | N/A | N/A | N/A | N/A | 0.08-0.2x | 0.42+0.2x | 0.01-0.1x | 0.14+0.1x |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.08), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| PROVECTUS BIOPHARMS PVCT | FY2025 | $336K | N/A | N/A | $21.0M | — |
| HARVARD APPRATS REG TCH HRGN | FY2025 | $704K | -$6.9M | N/A | $45.6M | — |
| ACCUSTEM SCIENCES INC ACUT | FY2025 | N/A | -$1.8M | N/A | $2.4M | — |
Where PROVECTUS BIOPHARMS Ranks
Frequently Asked Questions
What is PROVECTUS BIOPHARMS's annual revenue?
PROVECTUS BIOPHARMS (PVCT) reported $336K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is PROVECTUS BIOPHARMS's revenue growing?
PROVECTUS BIOPHARMS (PVCT) revenue declined by 45.5% year-over-year, from $617K to $336K in fiscal year 2025.
What is PROVECTUS BIOPHARMS's operating cash flow?
PROVECTUS BIOPHARMS (PVCT) recorded an outflow of $3.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are PROVECTUS BIOPHARMS's total assets?
PROVECTUS BIOPHARMS (PVCT) had $698K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does PROVECTUS BIOPHARMS spend on research and development?
PROVECTUS BIOPHARMS (PVCT) invested $1.9M in research and development during fiscal year 2025.
What is PROVECTUS BIOPHARMS's current ratio?
PROVECTUS BIOPHARMS (PVCT) had a current ratio of 0.08 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is PROVECTUS BIOPHARMS's P/E ratio?
PROVECTUS BIOPHARMS (PVCT) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $21.0M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is PROVECTUS BIOPHARMS's price-to-sales ratio?
PROVECTUS BIOPHARMS (PVCT) trades at 62.5x sales, its market capitalization divided by revenue of $336K revenue, FY2025. The market capitalization is $21.0M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does PROVECTUS BIOPHARMS's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, PROVECTUS BIOPHARMS (PVCT) held $251K in cash, cash equivalents and investments, and reported an operating cash outflow of $3.3M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is PROVECTUS BIOPHARMS's debt-to-equity ratio negative or not reported?
PROVECTUS BIOPHARMS (PVCT) has negative shareholder equity of -$6.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.